Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Titel:
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Auteur:
Zehentmayr, Franz Feurstein, Petra Ruznic, Elvis Langer, Brigitte Grambozov, Brane Klebermass, Marisa Hüpfel, Herbert Feichtinger, Johann Minasch, Danijela Heilmann, Martin Breitfelder, Barbara Steffal, Claudia Gastinger-Grass, Gisela Kirchhammer, Karoline Kazil, Margit Stranzl, Heidi Dieckmann, Karin